

1 **Iron-saturated bovine lactoferrin: A promising chemopreventive agent for**
2 **hepatocellular carcinoma**

3

4 **Supplementary Table 1. Effect of lactoferrin and sorafenib on HepG2 cells**
5 **viability *in vitro*. Cytotoxicity and combination index (CI)**

Treatment	Doses	24h	48h	72h
Holo-bLf	50 μ M	5.5 % \pm 0.16 ns	9.1 % \pm 0.05 ns	11 % \pm 0.02 ns
	100 μ M	17.5 % \pm 0.07 *	24.72 % \pm 0.06 ***	24.28 % \pm 0.18 ****
	200 μ M	67.77 % \pm 0.03 ****	71.96 % \pm 0.02 ****	78.61 % \pm 0.07 ****
Sorafenib	3 μ M	23.66 % \pm 0.02 **	51.01 % \pm 0.03 ****	62.59 % \pm 0.02 ****
	5 μ M	38.23 % \pm 0.03 ****	83 % \pm 0.01 ****	90.75 % \pm 0.01 ****
	7 μ M	63.1 % \pm 0.02 ****	88.96 % \pm 0.01 ****	98.49 % \pm 0.005 ****
Holo-bLf + Sorafenib	50 μ M 3 μ M	33.03 % \pm 0.05 **	91.44 % \pm 0.03 ****	98.79 % \pm 0.005 ****
Combination index		1.17	0.54	0.41

6

7 Cytotoxic effect = 100 - % of viability. Data represented as mean \pm SD, n = 3
8 ANOVA and Tukey's multiple comparisons tests were performed, and significant
9 differences were calculated compared with either the control group or specific
10 comparisons. (*P<0.005, **P<0.005, ***P<0.005 y ****P<0.0001).